PSC
PTX

Piper Sandler & Co’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Piper Sandler & Co’s Portfolio PTX Stock Details PTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-800
Closed -$47K – 158
2015
Q2 		$47K Buy
+800
New +$56.4K 0.03% 94

Other funds holding PTX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Piper Sandler & Co's PTX Position: Q3 2015 in Review

Piper Sandler & Co sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q3 2015, closing a stake of 800 shares — an estimated $47K sold.

Piper Sandler & Co first reported a position in PTX in Q2 2015 and held it in 1 quarter. The position peaked at $47K in Q2 2015. 104 funds tracked by Wall St. Rank hold PTX as of Q3 2015.

  • Piper Sandler & Co reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q3 2015 after selling out during the quarter.
  • Piper Sandler & Co sold 800 Pernix Therapeutics Holdings, Inc. shares in Q3 2015, an estimated $47K.
  • Piper Sandler & Co first reported a position in Pernix Therapeutics Holdings, Inc. in Q2 2015 and held it in 1 quarter.
  • Piper Sandler & Co's Pernix Therapeutics Holdings, Inc. position peaked at $47K in Q2 2015.
  • 104 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q3 2015.

Based on Piper Sandler & Co's 13F filing for Q3 2015, filed 16 Nov 2015.